Fibrogen Inc Stock Price, News & Analysis

FibroGen (NASDAQ: FGEN) has completed the sale of its China subsidiary to AstraZeneca for approximately $220 million, comprising $85 million in enterprise value and $135 million in net cash held in China. This amount represents a $60 million increase from initial guidance.

Following the transaction, FibroGen has repaid its term loan to Morgan Stanley Tactical Value for approximately $81 million and extended its cash runway into 2028. The company retains roxadustat rights in the U.S. and markets not licensed to Astellas (excluding China and South Korea).

The company plans to submit a Phase 3 protocol for roxadustat in anemia associated with lower-risk MDS in Q4 2025 and initiate a Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer in Q3 2025.

FibroGen (NASDAQ: FGEN) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025, in New York. CEO Thane Wettig will present on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel.

The presentation will be available via live webcast, and the management team will conduct one-on-one meetings with investors during the conference. A replay will be accessible on FibroGen's website in the Investors and Media section for 90 days following the event.

FibroGen (NASDAQ: FGEN) has received a crucial regulatory approval from the China State Administration for Market Regulation for the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. This approval marks a significant milestone in the transaction that was initially announced on February 20, 2025.

The deal remains subject to other contractual closing conditions and deliverables, with the transaction expected to close in the third quarter of 2025.

FibroGen (NASDAQ: FGEN) reported its Q2 2025 financial results and significant business updates. The company announced an increased total consideration of $210 million for the sale of FibroGen China to AstraZeneca, representing a $50 million increase from initial guidance. The transaction, expected to close in Q3 2025, includes an enterprise value of $85 million plus approximately $125 million in net cash.

Key financial results show Q2 2025 revenue of $1.3 million and a net loss of $13.7 million. The company reported $142.1 million in total consolidated cash and expects its cash runway to extend into 2028 post-China sale.

In clinical developments, FibroGen reached an agreement with the FDA on Phase 3 trial design for roxadustat in LR-MDS patients and plans to initiate a Phase 2 trial of FG-3246, their CD46-targeting ADC, in metastatic castration-resistant prostate cancer in Q3 2025.

[ "Sale of FibroGen China increased by $50 million to $210 million total consideration", "Cash runway expected to extend into 2028 after China sale closes", "FDA agreement reached on Phase 3 trial design for roxadustat in LR-MDS", "Net loss decreased significantly from $47.1M in Q2 2024 to $13.7M in Q2 2025", "Revenue increased 30% year-over-year to $1.3M in Q2 2025" ]

FibroGen (NASDAQ: FGEN) has received positive feedback from the FDA during a Type C meeting regarding roxadustat for treating anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell transfusion burden.

The feedback was based on promising post-hoc analysis data from the MATTERHORN Phase 3 trial, where roxadustat showed significant efficacy: 36% (8/22) of patients achieved transfusion independence versus 7% (1/15) in the placebo group. The company plans to initiate a new Phase 3 trial with approximately 200 patients, with the protocol submission expected in Q4 2025.

The planned study will be randomized, double-blind, and placebo-controlled, targeting patients requiring ≥4 pRBC units in consecutive 8-week periods who are refractory to, intolerant to, or ineligible for prior ESA therapy.

FibroGen (NASDAQ: FGEN) has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close. The company will host a conference call and webcast presentation at 5:00 PM Eastern Time on the same day.

The event will feature the FibroGen management team presenting financial results and providing a business update, followed by a live Q&A session. Investors can access the audio webcast through the company's website, and dial-in details will be provided upon registration.

FibroGen announced a 1-for-25 reverse stock split effective June 16, 2025, with split-adjusted trading beginning June 17 under the same FGEN symbol. The split will reduce outstanding shares from 101.1 million to approximately 4.0 million. This strategic move aims to boost the stock's per-share price to regain compliance with Nasdaq's minimum bid price requirement. The reverse split was approved by stockholders on June 4, 2025. Proportional adjustments will be made to equity incentive plans and outstanding equity awards. Stockholders with fractional shares will receive cash payments, and those holding electronic shares need not take action. Equiniti Trust Company is serving as the exchange agent for this corporate action.

FibroGen (NASDAQ: FGEN) has appointed Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. Dr. Kauffman brings 30 years of life sciences industry experience, particularly in oncology therapeutics, with expertise spanning preclinical research, clinical development, regulatory strategy, and global approvals. He currently serves as CEO, president, and board member of Nereid Therapeutics and holds board positions at several biotech companies. His notable achievements include co-founding Karyopharm and leading the global approval of XPOVIO®, serving as CMO at Onyx Pharma overseeing Kyprolis® development, and leading the Velcade® development program at Millennium Pharmaceuticals. Dr. Kauffman, who holds an MD and PhD from Johns Hopkins Medical School, joins FibroGen as the company positions itself for a potential turnaround with its pipeline of first-in-class assets.

FibroGen (NASDAQ: FGEN) reported its Q1 2025 financial results and business updates. The company announced an increased total consideration of $185 million for the sale of FibroGen China to AstraZeneca, up $25 million from initial guidance, with approximately $100 million in net cash held in China at closing. The transaction is expected to close in Q3 2025, extending the company's cash runway into 2H 2027. Key developments include the planned initiation of a Phase 2 monotherapy trial for FG-3246, their lead ADC targeting CD46 in metastatic castration-resistant prostate cancer, in Q3 2025. The company reported Q1 2025 revenue of $2.7 million, down from $25.4 million in Q1 2024, and a net loss of $16.8 million ($0.16 per share). FibroGen also filed a Type-C meeting request with the FDA regarding roxadustat for anemia associated with lower-risk myelodysplastic syndromes.